Kyowa Kirin is a global pharmaceutical company committed to developing innovative therapeutic solutions for patients with rare diseases. Our commitment to patients is reflected in a constant drive to address unmet medical needs and improve the management of rare and complex conditions.

Building on our expertise spanning clinical research, development, and treatment delivery, we leverage our scientific and technological capabilities across several therapeutic areas, notably X-linked hypophosphatemia (XLH), tumor-induced osteomalacia (TIO), and cutaneous T-cell lymphoma (CTCL).

Further information is available on our website: https://www.kyowakirinhub.com/en-gb/ [ou en-us selon votre cible]